5 Science Park at Yale
New Haven, CT 06511
Brian R. Dixon, Ph.D. - President & CEO - email@example.com
Antibiotics have long been recognized as reliable drugs that have largely overcome the lethal and devastating causes of bacterial infections. All known classes of antibiotics are increasingly encountering widespread resistance by many prevalent bacterial pathogens that will continue to significantly affect human health in the coming decades. BioRelix is a drug discovery and development company focused on identifying new anti-infective drug treatments that will address these critical challenges in infectious disease treatment.
BioRelix is discovering and developing new treatments for infectious diseases that target RiboSwitches – an innovative class of RNA drug targets found in pathogenic bacteria and fungi. RiboSwitches are short stretches of messenger RNAs that bind small molecule metabolites and control genes that are essential for the survival of many disease-causing microbes. Several different classes of RiboSwitch RNAs have been identified and each potentially could serve as a novel anti-infective drug target. BioRelix owns a worldwide license to develop and market RiboSwitch targeted medicines and is building a portfolio of products.
CT Employees: 12
World Employees: 12